Home › Research › Biomarkers
A longitudinal study of age-related traits and cognitive function: The Collaborative Amish Aging and Memory Project (CAAMP)
Jian, D. Z.; Laux, R. A.; Song, Y. E.; Lynn, A.; Miskimen, K.; Gulyayev, A.; Fuzzell, S. L.; Hochstetler et al.. medRxiv (preprint), 2026-09-20
Topic: Amyloid, tau and blood-test diagnosis
Structured AbstractO_ST_ABSINTRODUCTIONC_ST_ABSThe Collaborative Amish Aging and Memory Project (CAAMP) is an ongoing longitudinal study spanning multiple sites, focused on cognitive function and age-related traits in Midwestern Amish (Ohio and Indiana) communities. The primary traits of interest include Alzheimer Disease and related dementias (ADRD), successful aging (SA), and other age-related conditions. METHODSCAAMP integrates clinical and cognitive assessments with family history, genealogical, genomic, biospecimen, and biomarker data collected across Amish communities in Ohio and Indiana. Cognitive diagnoses are assigned through consensus adjudication using clinical, cognitive, functional, and informant data. RESULTSTo date, CAAMP has enrolled 3,978 participants (mean age 78.6 (SD = 7.9), 59.1% female, and 83% with an education level at the eighth grade), of whom 2,928 have consensus-adjudicated cognitive status. At the most recent assessment, 66.6% were cognitively unimpaired, 9.9% had mild cognitive impairment, 8.9% had Alzheimer disease, and 4.5% had cognitive impairment, but not Alzheimer disease. The remaining 1,050 did not have detailed cognitive evaluations at their enrollment. Longitudinal cognitive assessments and multiple biospecimen sample types are available for subsets of participants. CAAMP further includes extensive multigenerational pedigree information, genome-wide genotype and whole-genome sequencing data, and plasma biomarker measurements. DISCUSSIONCAAMP illuminates the genetic underpinnings of cognition and late life diseases, particularly Alzheimer Disease, by leveraging the special characteristics of a founder population. Continued study of this prospective cohort provides opportunities to identify the genetic and biological factors driving cognitive outcomes alongside other age-related conditions, advancing our understanding of both disease risk and protection.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jian, D. Z., Laux, R. A., Song, Y. E., Lynn, A., Miskimen, K., Gulyayev, A., et al. (2026). A longitudinal study of age-related traits and cognitive function: The Collaborative Amish Aging and Memory Project (CAAMP). medRxiv (preprint). https://doi.org/10.64898/2026.09.17.26363351
Vancouver
Jian DZ, Laux RA, Song YE, Lynn A, Miskimen K, Gulyayev A, et al. A longitudinal study of age-related traits and cognitive function: The Collaborative Amish Aging and Memory Project (CAAMP). medRxiv (preprint). 2026. doi:10.64898/2026.09.17.26363351.
BibTeX
@article{jian2026-1633fa73,
author = {Jian, D. Z. and Laux, R. A. and Song, Y. E. and Lynn, A. and Miskimen, K. and Gulyayev, A. and Fuzzell, S. L. and Hochstetler and others},
title = {{A longitudinal study of age-related traits and cognitive function: The Collaborative Amish Aging and Memory Project (CAAMP)}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.09.17.26363351},
url = {https://doi.org/10.64898/2026.09.17.26363351}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The remaining 1,050 did not have detailed cognitive evaluations at their enrollment.
- Longitudinal cognitive assessments and multiple biospecimen sample types are available for subsets of participants.
- CAAMP further includes extensive multigenerational pedigree information, genome-wide genotype and whole-genome sequencing data, and plasma biomarker measurements.
- DISCUSSIONCAAMP illuminates the genetic underpinnings of cognition and late life diseases, particularly Alzheimer Disease, by leveraging the special characteristics of a founder population.
- Continued study of this prospective cohort provides opportunities to identify the genetic and biological factors driving cognitive outcomes alongside other age-related conditions, advancing our understanding of both disease risk and protection.
Why it matters
This describes an ongoing long-term study of nearly 4,000 Amish participants that collects clinical, genetic, and biomarker data to study cognitive aging and Alzheimer's disease. It is a resource for future research and reports no results yet on treating, curing, or preventing the disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designprospective cohort
- Participants3,978
- Effect size59.1%; 66.6%; 9.9%
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 41 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomised / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 39 of the 94 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A prospective cohort study, followed forward from enrollment |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,978 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Jonathan L. Haines: h-index 127 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Case Western Reserve University: institution h-index 1,159 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 39 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 39 of the 94 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related studies in Biomarkers
Also tagged “cognitive-function”
1,118 studies in the library carry the topic tag “cognitive-function”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,118 tagged studies.